Tilray | TRLY - Assets


Tilray reported $2.1B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Acasti Pharma USD 68.49M 1.91M Dec/2025
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Aurora Cannabis CAD 601.09M 174.2M Mar/2026
Avita Medical AUD 56.39M 1.74M Dec/2025
Canopy Growth CAD 1.12B 12.54M Mar/2026
Cronos Group USD 1.18B 7.75M Jun/2026
Dianthus Therapeutics USD 1.21B 33.61M Jun/2026
Divis Laboratories Ltd INR 200.33B 18.82B Mar/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
IQVIA Holdings USD 29.88B 206M Jun/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Moderna USD 10.96B 527M Jun/2026
Organigram Holdings CAD 521.31M 9.36M Mar/2026
Organon & Co USD 13.18B 182M Jun/2026
Revvity USD 12.05B 49.24M Jun/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
Tilray USD 2.1B 15.95M Sep/2025
Viatris USD 35.04B 1.79B Jun/2026
Xeris Pharmaceuticals USD 411.9M 19.89M Jun/2026
Zealand Pharma A/S 15.3B 647.8M Mar/2026